These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 34872487

  • 1. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
    Chatterjee S, Chakraborty DS, Choudhury S, Lahiry S.
    Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487
    [Abstract] [Full Text] [Related]

  • 2. Cefiderocol: A Siderophore Cephalosporin.
    El-Lababidi RM, Rizk JG.
    Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
    [Abstract] [Full Text] [Related]

  • 3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 4. [Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection].
    Yamano Y, Morita I, Ariyasu M.
    Nihon Yakurigaku Zasshi; 2024 Feb; 159(5):331-340. PubMed ID: 39218681
    [Abstract] [Full Text] [Related]

  • 5. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
    Lee YR, Yeo S.
    Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
    [Abstract] [Full Text] [Related]

  • 6. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
    Syed YY.
    Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD.
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [Abstract] [Full Text] [Related]

  • 8. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, Kebriaei R, Rybak MJ.
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [Abstract] [Full Text] [Related]

  • 9. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD.
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of carbapenems and alternative antimicrobials for treating complicated urinary tract infections caused by third-generation cephalosporin-resistant gram-negative bacteria: A systematic review and meta-analysis of randomised controlled trials.
    Maeda M, Sunaga T, Sato MT, Hasegawa T, Noma H, Ota E.
    J Infect Chemother; 2024 Nov; 30(11):1147-1155. PubMed ID: 38705237
    [Abstract] [Full Text] [Related]

  • 11. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.
    Kawaguchi N, Katsube T, Echols R, Wajima T.
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29038272
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A, Zeitlinger M.
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [Abstract] [Full Text] [Related]

  • 13. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
    Ong'uti S, Czech M, Robilotti E, Holubar M.
    Clin Infect Dis; 2022 Apr 09; 74(7):1303-1312. PubMed ID: 34492098
    [Abstract] [Full Text] [Related]

  • 14. Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens.
    Bonomo RA.
    Clin Infect Dis; 2019 Nov 13; 69(Suppl 7):S519-S520. PubMed ID: 31724046
    [Abstract] [Full Text] [Related]

  • 15. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
    Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD.
    J Antimicrob Chemother; 2021 May 12; 76(6):1379-1391. PubMed ID: 33532823
    [Abstract] [Full Text] [Related]

  • 16. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
    Lodise TP, Bonine NG, Ye JM, Folse HJ, Gillard P.
    BMC Infect Dis; 2019 Aug 14; 19(1):718. PubMed ID: 31412809
    [Abstract] [Full Text] [Related]

  • 17. Clinical experience of cefiderocol.
    Fariñas MC.
    Rev Esp Quimioter; 2022 Sep 14; 35 Suppl 2(Suppl 2):35-38. PubMed ID: 36193983
    [Abstract] [Full Text] [Related]

  • 18. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.
    Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.
    Antimicrob Agents Chemother; 2018 Feb 14; 62(2):. PubMed ID: 29158270
    [Abstract] [Full Text] [Related]

  • 19. Cefiderocol to treat complicated urinary tract infection.
    McCarthy MW.
    Drugs Today (Barc); 2020 Mar 14; 56(3):177-184. PubMed ID: 32282864
    [Abstract] [Full Text] [Related]

  • 20. [Discovery of a New Siderophore Cephalosporin, Cefiderocol].
    Yamano Y.
    Yakugaku Zasshi; 2024 Mar 14; 144(6):627-631. PubMed ID: 38825471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.